Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals Q4 2023 Earnings Report

Reviva Pharmaceuticals logo
$0.88 -0.09 (-9.30%)
Closing price 04:00 PM Eastern
Extended Trading
$0.89 +0.01 (+0.68%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals EPS Results

Actual EPS
-$0.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Reviva Pharmaceuticals' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Reviva Pharmaceuticals Earnings Headlines

What is Zacks Small Cap's Forecast for RVPH Q2 Earnings?
When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Research Analysts Set Expectations for RVPH Q2 Earnings
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

View Reviva Pharmaceuticals Profile

More Earnings Resources from MarketBeat